胃腸および消化器系

抽象的な

COVID-19 and Liver injury: hepatology perspectives

Natassia Vianna Bocchese, Noele Gurgel Dávila, Maria Beatriz Maia Rodrigues, Irami Araújo-Neto, Mariana de Oliveira Costa, Diniz de Meiroz Grillo Barbalho, Amália Cinthia Meneses Rêgo and Irami Araújo-Filho

SARS-CoV-2, a severe acute respiratory syndrome caused by Coronavirus 2, discovered in 2019 in China, is responsible for the current pandemic declared by the WHO since March 2020. The clinical syndrome caused by Covid-19 has a broad spectrum of severity. The most common clinical manifestations are fever, dry cough, dyspnea, fatigue, and anosmia. The virus binds to receptors for angiotensin-converting enzyme 2 (ECA2) and serine protease TMPRSS2 for protein S initiation, which are expressed not only in the lungs but also in the liver, colonic, esophageal and biliary epithelial cells. In this context, the liver is a potential target for COVID-19 infection. Liver damage occurs during the course and treatment of viral infection in patients with or without previous liver disease. Therefore, the characteristics of liver injury associated with COVID-19 were reviewed based on research related, in the context of the pandemic.